Eric J. Leire Joins ParinGenix Inc. As CEO; Pipeline Update 
10/19/2005 5:09:02 PM

TUCSON, Ariz.--(BUSINESS WIRE)--July 28, 2005--ParinGenix, an early-stage drug development company, has named Eric J. Leire, M.D., M.B.A., as chief executive officer. ParinGenix is developing multiple products based on a modified form of heparin. The company plans to initiate multiple Phase II trials for evaluation of its lead product, PGX-100, in acute exacerbations of chronic obstructive pulmonary disease (COPD) and in cardiac ischemia-reperfusion injury following myocardial infarction. The company is currently completing U.S. Phase I clinical trials to examine the safety and pharmacokinetics of PGX-100 in healthy volunteers in support of these critical care indications. Additional products based on the modified heparin are in preclinical development for other critical-care and chronic indications.